Austria

Themis Bioscience

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

AUSTRIA Austria

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Merck to Acquire Themis

Lead Product(s): SARS-CoV-2 vaccine

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Vaccine

Partner/Sponsor/Collaborator: Merck & Co. Inc.

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Acquisition May 26, 2020

Details:

The planned acquisition builds upon an ongoing collaboration between the two companies to develop vaccine candidates using the measles virus vector platform, and is expected to accelerate the development of Themis’ COVID-19 vaccine candidate.

Marinomed Biotech

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

AUSTRIA Austria

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Marinomed Receives FFG Funding to Research SARS-Cov-2 Therapy Based On Carragelose®

Lead Product(s): Carragelose

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Large molecule

Partner/Sponsor/Collaborator: Austrian Research Promotion Agency

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Funding April 28, 2020

Details:

Funding is directed towards a trial which will clinically test an inhalation solution with Carragelose® as an acute treatment for viral pneumonia caused by SARS-CoV-2 or other respiratory viruses.

Apeiron Biologics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

AUSTRIA Austria

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

APEIRON’s respiratory drug product to start pilot clinical trial to treat coronavirus disease COVID-19 in China

Lead Product(s): APN01

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 26, 2020

Details:

The randomized, unblinded trial will treat 24 patients for seven days to obtain preliminary data on the impact of rhACE2 on biological, physiologic, and clinical outcomes and safety in patients.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Product Type

Companies

Themis Bioscience

Merck to Acquire Themis

Marinomed Biotech

Marinomed Receives FFG Funding to Research SARS-Cov-2 Therapy Based On Carragelose®

Apeiron Biologics

APEIRON’s respiratory drug product to start pilot clinical trial to treat coronavirus disease COVID-19 in China